Vanda Pharmaceuticals (VNDA) Operating Income (2010 - 2026)
Vanda Pharmaceuticals (VNDA) reported Operating Income of -$50.2 million for Q1 2026, down 22.41% on a YoY basis from -$64.7 million in Q1 2025, and down 24.46% sequentially from -$40.4 million in Q4 2025.
Vanda Pharmaceuticals (VNDA) Operating Income (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals (VNDA) has 17 years of Operating Income data on file, last reported at -$50.2 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income fell 22.41% year-over-year to -$50.2 million; the trailing twelve-month figure through Mar 2026 stood at -$160.4 million (down 121.34% YoY), and the FY2025 full-year result was -$151.2 million, down 271.79% from the prior year.
- Operating Income fell to -$50.2 million in Q1 2026, from -$40.4 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $6.6 million in Q4 2022 to a low of -$50.2 million in Q1 2026.
- A 5-year average of -$14.7 million and a median of -$9.2 million in 2024 frame the typical range for Operating Income.
- Across the five-year window, Operating Income jumped 126.13% in 2023 and sank 560.83% in 2024, its largest moves.
- Tracing VNDA's Operating Income over 5 years: stood at $6.6 million in 2022, then plunged by 207.01% to -$7.1 million in 2023, then sank by 44.9% to -$10.3 million in 2024, then sank by 292.58% to -$40.4 million in 2025, then retreated by 24.46% to -$50.2 million in 2026.
- Business Quant data shows VNDA's Operating Income at -$50.2 million in Q1 2026, -$40.4 million in Q4 2025, and -$31.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Vanda Pharmaceuticals | 318.71 Mn | 116.40 Mn | 48.56 Mn | -50.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.22 Mn |
| Dec 31, 2025 | -40.35 Mn |
| Sep 30, 2025 | -31.28 Mn |
| Jun 30, 2025 | -38.50 Mn |
| Mar 31, 2025 | -41.03 Mn |
| Dec 31, 2024 | -10.28 Mn |
| Sep 30, 2024 | -11.00 Mn |
| Jun 30, 2024 | -10.15 Mn |
| Mar 31, 2024 | -9.24 Mn |
| Dec 31, 2023 | -7.09 Mn |
| Sep 30, 2023 | -6.00 Mn |
| Jun 30, 2023 | -2.87 Mn |
| Mar 31, 2023 | 2.00 Mn |
| Dec 31, 2022 | 6.63 Mn |
| Sep 30, 2022 | 3.91 Mn |
| Jun 30, 2022 | 3.46 Mn |
| Mar 31, 2022 | -7.67 Mn |
| Dec 31, 2021 | 8.64 Mn |
| Sep 30, 2021 | 10.82 Mn |
| Jun 30, 2021 | 12.37 Mn |